Xenon Q1 net loss $19.7M; XEN1101 Phase 3 on track for H2 2022

Xenon Pharmaceuticals Inc.

2023-Q1 EPS reported -$0.35 revenue$8,766,000

Net loss $19.7M vs $15.8M YoY; revenue $8.8M, up from $4.4M on Neurocrine milestone.
Cash $537.9M, sufficient to fund operations into at least 2024.
XEN1101 Phase 2b met primary endpoint; FDA End-of-Phase 2 meeting Q2 2022; Phase 3 start H2 2022.
Phase 2 X-NOVA for MDD initiated; topline results expected in 2023.
XEN496 Phase 3 EPIK in KCNQ2-DEE ongoing; completion anticipated in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.